Christian Itin, Ph.D., Chairman and CEO
London, UK
Autolus is a biopharmaceutical company founded on advanced cell programming technology pioneered by Dr. Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T-cell product candidates. Autolus is committed to bringing life-changing treatments to cancer patients by reprogramming their own T-cells to combat the treatment of haematological malignancies and solid tumours. Autolus believe its programmed T-cell therapies have the potential to offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.

By using this website you agree to accept our Privacy Policy and Terms & Conditions